Sina Khorsandi

4 weeks ago | advanced.onlinelibrary.wiley.com | Sina Khorsandi |Kristin Huntoon |Yifan Wang |Adam Woodward

1 Introduction The clinical successes of immune checkpoint inhibitors (ICIs) have ushered in a renaissance era for immunotherapy, as ICIs are now the standard-of-care for many cancer types.[1] However, patient response to ICIs remains highly heterogeneous, with the majority of patients showing little to no response at all.[2] A potential reason for the low efficacy seen in many patients is from a lack of innate immune activation.